Fractyl Health

Fractyl Health is a pioneering company focused on developing innovative therapies to tackle the underlying cause of type 2 diabetes. Established in 2010, it is dedicated to reversing the metabolic disease epidemic through novel therapeutic interventions. The company's lead program, Revita DMR, represents a first-in-class procedural therapy that is currently in late-stage clinical trials for treating type 2 diabetes. The uniqueness of Fractyl Health's approach lies in its emphasis on the intestine's role in metabolic control, as supported by groundbreaking research and biological insights. The company's strategies are tailored to target and regulate this crucial element in the treatment of metabolic diseases, offering a fresh perspective in the field of biotechnology and health care. Fractyl Health's recent Series F investment on 15th August 2022 saw participation from a consortium of esteemed investors, including Bessemer Venture Partners, GV, Mithril Capital, True Ventures, Domain Associates, Emergent Medical Partners, General Catalyst, Catalio Capital Management, Taiwania Capital Management Corporation, and CDIB Ventures. The company is based in Lexington, Massachusetts. Fractyl Health's mission, coupled with its strong investor support and location within the United States, reinforces its position as a promising player in the fight against metabolic diseases, particularly type 2 diabetes. With a dedicated team of passionate innovators at the intersection of biology and technology, Fractyl Health is poised to deliver significant real-world impacts for individuals affected by metabolic disease.